#USA #Paris #Nuclear Medicine #Theranostics #DOSIsoft

DOSIsoft Launches DOSIsoft Theranostics

On May 26, 2026, DOSIsoft, a prominent name in dosimetry software for both radiation oncology and nuclear medicine, officially introduced DOSIsoft Theranostics. This dedicated branch aims to enhance and innovate software solutions tailored for personalized nuclear medicine, particularly in the field of theranostics, just ahead of the SNMMI 2026 conference.

The establishment of DOSIsoft Theranostics marks a strategic move towards supporting a broader clinical and industrial ecosystem. By acting as an independent entity, it can focus solely on the demands of theranostics, positioning itself as a reliable partner for software solutions. The entity is equipped for autonomy, enabling it to explore innovative partnerships and make long-term investments conducive to the evolution of the field.

Theranostics—a fusion of diagnostic imaging and targeted therapy—is experiencing significant growth. DOSIsoft, with its extensive experience spanning over two decades, is well-placed to drive innovations in software solutions that support radiopharmaceutical therapies. This focus on innovation not only aims to improve clinical processes but also to integrate advanced methodologies, such as quantitative imaging and AI-driven workflows, enabling a more personalized approach to patient care.

The core of this new initiative lies in the flagship software platform, PLANET®. Originally designed for external beam radiation therapy treatment planning, PLANET® has evolved into a versatile platform that boasts enhanced voxel-based dosimetry capabilities along with comprehensive DICOM interoperability. This software is FDA 510(k) cleared and CE marked, ensuring its validity and reliability in clinical settings. Currently, PLANET® serves numerous leading hospitals and educational centers around the globe, thanks to its vendor-neutral framework that allows clinicians to adapt it to various clinical protocols and therapy strategies.

Marc Uszynski, the CEO of DOSIsoft, emphasized that the creation of a dedicated theranostics organization showcases the company's long-term commitment to this rapidly advancing domain. By establishing DOSIsoft Theranostics, the company gains the ability to expedite innovation, foster new collaborations, and broaden the applications of theranostics across global markets.

The company will also be showcasing its offerings at the SNMMI 2026 event, where attendees can explore the full capabilities of DOSIsoft Theranostics and its contributions to the evolving landscape of nuclear medicine.

DOSIsoft traces its roots back to 2002 and has grown into a market leader in dosimetry software within the realms of radiation oncology and nuclear medicine. The company is devoted to enhancing the quality of cancer treatments and ensuring patient safety. With an impressive tally of over 1,000 installations spanning 800+ hospital centers across 80 countries, DOSIsoft continues to provide forward-thinking solutions for radiation therapy quality assurance, personalized dosimetry, and theranostics.

Through collaborations with eminent cancer treatment centers globally, DOSIsoft is also a participating partner in the European Thera4Care project, dedicated to building a supportive ecosystem for personalized cancer care. The launch of DOSIsoft Theranostics signals an exciting new chapter in this journey to redefine cancer treatment.

The future looks promising as DOSIsoft Theranostics gears up to make significant strides, ensuring that personalized medicine continues to advance in capabilities and accessibility, ultimately benefiting patients worldwide.